



Recommended Vaccination Schedule and Intervals for MCV4¹ (Meningococcal Conjugate Vaccine)

Age	Subgroup	Primary Vaccination	Booster Dose
9 through 23 months of age with high risk condition	Children with complement component deficiencies; travel to endemic areas; part of community outbreak	Two doses of MCV4; 3 months apart ² (may give 2 months apart ² prior to travel)	1 st booster dose in 3 years then every 5 years for complement component deficiencies; Booster dose for travel/outbreak based on risk; If needed 1 st dose in 3 years then every 5 years
2 through 55 years of age with high risk condition	Persons with functional or anatomic asplenia ³ ; complement component deficiencies	Two doses of MCV4 2 months apart ²	Aged 2-6 years: 1 st booster dose in 3 years then every 5 years thereafter Aged 7-55 years: Booster dose every 5 years
9 months through 55 years with high risk condition	Persons with HIV if another indication for meningococcal vaccination exists ^{4, 5}	Two doses of MCV4 ² Interval varies by age (see groups above)	If first dose received at aged 2 through 6 years and remains at increased risk for disease ⁵ , should receive an additional dose of MCV4 3 years after primary vaccination
2 through 55 years of age with high risk condition	Persons who: <ul style="list-style-type: none"> ▪ Travel to or are residents of endemic areas ▪ Travel to Mecca for annual Hajj ▪ Military recruits ▪ Microbiologist exposed to <i>N. meningitidis</i> ▪ Part of community outbreak of a vaccine-preventable serogroup (ACYW) 	One dose of MCV4	If first dose received at age 7 years or older and remains at increased risk for disease ⁵ , should receive an additional dose of MCV4 5 years after primary vaccination If persons in either of the age groups above remain at increased risk for disease ⁵ , booster dose should be repeated every 5 years thereafter
11 through 18 years of age, not in a risk group listed above	Adolescents	Routine vaccination: One dose of MCV4 at aged 11-12 years Catch-up vaccination: One dose of MCV4 to persons aged 13-18 years not previously vaccinated	If vaccinated at aged 11-12 years, should receive a one-time booster dose at age 16 years ² If vaccinated at aged 13 through 15 years, should receive a one-time booster dose at age 16 through 18 years ² If first dose is given at age 16 years or older, a booster dose is not needed
19 through 21 years of age	Persons entering college/living in a dormitory Consider for persons currently attending college	Ensure at least one dose of MCV4 was given in last 5 years	Doses not routinely recommended at/after age 22 years
56 years of age and older	Persons age 56 years & older: use MPSV4 (meningococcal polysaccharide vaccine) if vaccination is indicated	For all risk groups, give one primary dose of MPSV4	Booster dose should be considered based on the risk group. Refer to categories above (persons aged 2 through 55 years) to determine need.

¹ MCV4 brands: Menactra® (sanofi pasteur) is licensed for aged 9 months-55 years; Menveo® (Novartis) is for aged 2-55 years

² Minimum interval between doses for all ages is 8 weeks

³ For children with asplenia, complete PCV series (including at least one dose of PCV13) & then give MCV4 at least 4 weeks later

⁴ HIV infection, without another risk factor present, is not a medical indication for meningococcal vaccination

⁵ Risk groups: adolescents, travel (endemic areas, Mecca during Hajj), outbreak, microbiologist exposed to *N. meningitidis*, military